Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

Video

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the phase II ALTA trial, which is exploring brigatinib (Alunbrig) in crizotinib (Xalkori)-refractory patients with ALK-positive non—small cell lung cancer, during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

There is now an embarrassment of riches regarding ALK inhibitors, one of which is brigatinib, Camidge explains. In the ALTA trial, 2 doses of brigatinib were explored: 90 mg and 180 mg, the latter of which was given after 7 days of the 90-mg dose of brigatinib. The median progression-free survival (PFS) with the 90-mg dose is about 9 months; however, the 180-mg dose with the median PFS is now over 16 months, Camidge says.

Now, Camidge questions whether these findings will translate into better efficacy when used in the first-line setting.

<<< View more from the World Conference on Lung Cancer

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania